Skinbiotherapeutics Share Discussion Threads

[bobalot] 17/11/2017 14:11

I am however sticking with SkinBio as they have an excellent business model and near term prospects for commercialisation and a steady pipeline of valuable patents that will include skin and nail fungus treatments and may extend to a new family of antibiotics.


Asterix96 17 Nov '17 - 16:10 - 850 of 852    0   0 (Filtered)

[incanus] 17/11/2017 13:03

Bob, in your opinion how do you expect OPTI to "release value BACK to shareholders?"
Fair question.

[slartybartfaster] 17/11/2017 11:25

Awkward questions do confound some. Best hide then lol

[bobalot] 17/11/2017 10:52

HERE IS A RECENT COMMENT ABOUT HUMAN TESTING due to start around Q2.

SkinBiotix, the company's microbiome platform, will be tested in a cosmteic consumer efficacy study, a far less demanding process than clinical trials.

Around sixty patients will be involved in the study for a month and if successful, it will be allowed on sale almost immediately.

THAT MEANS THE PRODUCT WILL BE COMMCIALY AVAILABLE NEXT YEAR FOLLOWING HUMAN TESTING.

[bobalot] 17/11/2017 10:26

Here is a very good summary of exactly where the business development is at --- THE DEVELOPMENT OF SKIN RELATED PRODUCTS IS DEVELOPING FAST WITH NEW PRODUCTS IN THE OFFERING.


SkinBioTherapeutics technology gets double green light - next stop human studies


Researchers at Charles River Laboratories assessed for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells)

The company's first product will be a skincare cosmetic

SkinBioTherapeutics PLC (LON:SBTX) said its SkinBiotix technology has passed two additional and final toxicity tests, meaning it is safe to use in the companyâ€;™s three target markets.

Researchers at Charles River Laboratories assessed for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells).

Prior to that, SkinBiotix was found not to be cytotoxic, which in layman’s terms meant it didn’t kill cells it came in contact with.

Focusing on efficacy

"Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focusing on further proving its efficacy,âS64;� said Dr Catherine O'Neill, chief executive of SkinBioTherapeutics.

The company is focused on developing products and treatments that effect the portion of the human microbiome that resides on the skin.

This is a mix of bacteria, yeasts, and parasites that live on the body’s biggest organ.  Sounds gross, but this microbial ecosystem is thought to be key to skin health.

Based on the work of CEO Oâ€͐2;Neill at Manchester University, the SkinBiotix platform is protected by three patent families and 18 patent applications.

It is also supported by a host of peer-reviewed academic publications and has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.

As mentioned above, the firm is developing three products that manage, protect and restore the body’s outer layer.

First cab off the rank

First cab off the rank will be the companyâ€;™s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.

The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes.

Human trials

Earlier this week SkinBioTherapeutics said it expects a study in people of a cosmetic skin care cream next year to be the start of serious commercialisation talks.

Tentative discussions have already begun, said CEO Neill, but human data is crucial to the process.

In the release Thursday, the company said it was confident of human studies getting underway next year.

www.proactiveinvestors.co.uk/companies/news/186987/skinbiotherapeutics-technology-gets-double-green-light-next-stop-human-studies-186987.html

[bobalot] 17/11/2017 10:13

slartybartfaster 17 Nov '17 - 00:14 - 842 of 842    0   0 FILTERED

what an idiot

[slartybartfaster] 17/11/2017 00:14

Deny your wrong all you like, the truth will out and your indepth research will be exposed. I noticed you swerved elricos question. lol

[bobalot] 16/11/2017 21:59

slartybartfaster --- utter nonsense!.

[slartybartfaster] 16/11/2017 19:19

Fss bob, what do you want, neons. Accept you are wrong simple. You look more of an idiot with each post. Not good for someone attempting to an authority on sbtx, especially with the rns pops up announcing the divi. Do want soh to address it to you!

[bobalot] 16/11/2017 17:09

So where is the RNS making that announcement?.

And I hope people like you and others are not disappointed if OPTI under delivers.

[elrico] 16/11/2017 16:26

Bob - Last word on the subject of SBTX share...well, not my words, but SOH from an email exchange on this and other topics. There was also a phone call where in-specie divi was used, which has been repeated by SOH. All I would ask of you, Bob, in your opinion how do you expect OPTI to "release value BACK to shareholders?"

Thanks Elric,
Our emails crossed over as I sent a quick response last night whilst travelling. I always value your insight and agree with the issues. Just to help in terms of guidance:-

1. We have always made clear our approach to SBTX which was outlined in my presentations at the Investor Show and recent investor meeting
a. Our focus is on building value in SBTX
b. Our aim is release value back to shareholders without unduly impacting on both SBTX and OPTI value
c. We are working on the best way of achieving this with our advisors
d. We hope to have the details worked out in the near future and announced so shareholders will see how they can benefit

[bobalot] 16/11/2017 15:19

Even more TW ramping quotes. Pleased to hear OPTI is doing well. But the notion of free stock being given away with certain conditions without an RNS as a plan leaked by TW smells of being too good to be true.

As SkinBio has the potential to significantly rise ten fold PI's will be far better served by investing in SBTX at current values.

Popular Medical products tend to rise far higher that food ingredient firms making SkinBio a STRONG BUY.



slarty -- when I read that TW article quite a while back I SOLD OUT OF OPTI.

[bobalot] 16/11/2017 15:06

There are a load of unknowns about the fabled Free SBTX shares for OPTI holders especially when the SkinBio share price rises.

It sounds more like a carrot and stick approach authored by TW.

[rafboy] 16/11/2017 14:07

Thanks Elric, yes I have some SBTX just in case LOL.

[elrico] 16/11/2017 13:55

Raf - It has been a bone of contention for me, which I made my feelings known to SOH at the time. OPTI holders will be paid an "in specie divi retrospectively." This suggests to me existing OPTI holders will qualify for SBTX shares, presumably, IPO to to-date. I have NO firm evidence for this other than what appears to be a key wording; "retrospective." TW has previously stated 1% for 1%. However, the maths don't stack up for me on that one....a whole new topic. ;)

I wasn't taking any chances, I bought a few SBTX anyway.

[rafboy] 16/11/2017 13:34

Elrico, Has the "record date" for holding OPTI shares ever been published or announced? A serious question as I have family members who hold OPTI but not all from a year or more ago. They believe if a date has not been announced then they should be entitled to SBTX shares in line with their OPTI holding.

[bobalot] 16/11/2017 12:35

Some of the intel you publish is useful and welcome.

However we have a difference of opinion but I hope we can continue to discuss in a civilised way. Wishing all OPTI investors the best of good fortune.

[elrico] 16/11/2017 12:29

Bob - I'm trying to help you, not ridicule you. My facts are correct. I have said all I need to on the subject. Just remember who told you...as for rose tinted...you appear to be wearing a pair yourself.

I wish you luck.

[bobalot] 16/11/2017 12:27

That was an epic RAMP from TW....woof, woof...lol
slarty stay with it if OPTI makes you happy fine.

THIS IS THE SKINBIO THREAD, wink....go evangelise your message on the OPTI thread.

[slartybartfaster] 16/11/2017 12:23

Bob from tw in his march newsletter. 'At some stage Optibiotix will distribute those shares to we lucky shareholders in Optibiotix and since we do not know the record date on that distribution folks would be barking mad to sell.' You have it wrong, period.

[bobalot] 16/11/2017 12:09

I know the key facts without ROSE COLOURED GLASSES.....however good luck...I prefer the sister company --- SkinBio lol.

[elrico] 16/11/2017 12:03

Bob - OPTI used shareholder funds to invest in SkinBiotix. You seem to be implying OPTI BOD have feathered their own nest by spinning out SBTX, and issuing shares to a select few within the teams at SBTX and OPTI and screwed OPTI PI's. Like it or not, or understand it or not, OPTI PI's have a right to 41.9% of SBTX and SOH is on record stating qualifying PI's will be paid an "in specie divi" at an appointed time. OPTI recently cancelled several million shares from its register, this was part of the admin phase AHEAD of the distribution. I suspect (ONLY MY OPINION for what its worth) OPTI will distribute some of the shares post the 12 month lock-in period. I would hope they have T&C attached to prevent a sell-off - I'm sure we will learn soon enough. In any event, you appear to be in for a shock!

You appear to have invested in a company without knowing key facts which could have a material impact on your investment and thrown away free SBTX shares in the process. Oh the irony!

[bobalot] 16/11/2017 12:00

Best for you to ask TW and his team....lol.

I prefer to discuss issues about SBTX --- I sold OPTI a while back and made a descent profit.

SkinBio has huge growth potential and once a commercial deal is announced the CEO has said will be an inflection point for the share price ...which means a steep rise will be in the offering during late Q3 or early Q$ next year.


I actually look upon the promise of free SBTX shares issued by OPTI as PIE IN THE SKY. If the company make a maiden special dividend it will most likely be around 0.5%. If that translates into SBTX stock after all the legal permissions have been sought and agreed, which seems convoluted and unrealistic, OPTI investors will get free stock UNDER CERTAIN CONDITIONS. Which are currently unknown to the public.


WHILE SBTX IS PRICED AROUND 10P PI's will do a lot better to BUY now rather than being potentially disappointed later, especially if the share price rises significantly-effectively diluting the free share scenario.